At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNCX Quince Therapeutics, Inc.
Market Closed 07-10 16:00:00 EDT
17.54
+0.05
+0.29%
盘后17.54
+0.000.00%
19:24 EDT
High17.70Low17.23Vol23.63K
Open17.44D1 Closing17.49Amplitude2.69%
Mkt Cap17.15MTradable Cap15.40MTotal Shares977.97K
T/O413.70KT/O Rate2.69%Tradable Shares878.20K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quince Therapeutics Appoints Paul Yu to Chair New Pulmonary Scientific Advisory Board
Reuters  ·  06-30
Quince Therapeutics Appoints Paul Yu to Chair New Pulmonary Scientific Advisory Board
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
THOMSON REUTERS  ·  06-30
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
Take-Two, Quince, Tonix, CoreWeave, Affirm Trending With Analysts
TIPRANKS  ·  06-27
Take-Two, Quince, Tonix, CoreWeave, Affirm Trending With Analysts
Quince Therapeutics Amends 8-K to Correct Reverse Stock Split Description
Reuters  ·  06-27
Quince Therapeutics Amends 8-K to Correct Reverse Stock Split Description
Quince Therapeutics files Form 3 for director, Chief Corporate Affairs Officer Brigette Roberts
Reuters  ·  06-12
Quince Therapeutics files Form 3 for director, Chief Corporate Affairs Officer Brigette Roberts
Quince Therapeutics shareholders approved reverse stock split authorization range of 1-for-10 to 1-for-100
Reuters  ·  06-12
Quince Therapeutics shareholders approved reverse stock split authorization range of 1-for-10 to 1-for-100
Quince Therapeutics regains Nasdaq listing compliance after equity rises to $15.67 million
Reuters  ·  05-22
Quince Therapeutics regains Nasdaq listing compliance after equity rises to $15.67 million
Quince Therapeutics announces LAM-001 data
TIPRANKS  ·  05-18
Quince Therapeutics announces LAM-001 data
Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed
TIPRANKS  ·  05-18
Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed
Quince Therapeutics prices private placement raising up to $187 million
Reuters  ·  05-18
Quince Therapeutics prices private placement raising up to $187 million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Reuters  ·  05-18
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Quince Therapeutics acquires Orphai Therapeutics, adds inhaled rapamycin program LAM-001
Reuters  ·  05-18
Quince Therapeutics acquires Orphai Therapeutics, adds inhaled rapamycin program LAM-001
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
THOMSON REUTERS  ·  05-18
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Quince Therapeutics reports Phase 2a LAM-001 gains in PH-ILD patients
Reuters  ·  05-18
Quince Therapeutics reports Phase 2a LAM-001 gains in PH-ILD patients
Quince Therapeutics - Lam-001 Generally Well Tolerated in Phase 2a Study
THOMSON REUTERS  ·  05-18
Quince Therapeutics - Lam-001 Generally Well Tolerated in Phase 2a Study
Quince Therapeutics - Lam-001 Phase 2a in Ph-Ild Shows 67.4M 6Mwd Improvement, 33.9% Pvr Reduction at 24 Weeks
THOMSON REUTERS  ·  05-18
Quince Therapeutics - Lam-001 Phase 2a in Ph-Ild Shows 67.4M 6Mwd Improvement, 33.9% Pvr Reduction at 24 Weeks
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in Pah and Ph-Ild
THOMSON REUTERS  ·  05-18
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in Pah and Ph-Ild
Quince Therapeutics - Phase 2B Trial in Ph-Ild to Start Mid-2026, Topline Data Expected Q1 2028
THOMSON REUTERS  ·  05-18
Quince Therapeutics - Phase 2B Trial in Ph-Ild to Start Mid-2026, Topline Data Expected Q1 2028
Quince Therapeutics swings to Q1 net income of $35.91 million; operating loss narrows 2% to $14.59 million
Reuters  ·  05-12
Quince Therapeutics swings to Q1 net income of $35.91 million; operating loss narrows 2% to $14.59 million
Quince Therapeutics Inc expected to post a loss of $2.56 a share - Earnings Preview
Reuters  ·  05-08
Quince Therapeutics Inc expected to post a loss of $2.56 a share - Earnings Preview

Introduction

Company Name.
Quince Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Issue price:
--